Rat Man - Obama Administration Not Finished Yet With

New Post Public Reply Private Reply Replies (1) Message Board
PoemStone cashclan #14038
Rat Man - Obama Administration Not Finished Yet With Executive Actions, Regulations



On Monday, President Barack Obama issued his fifth executive order since the Nov. 8 election. In this case, it was to create a National Invasive Species Council to compile a report by 2020 on how to prevent such species from affecting climate change, food safety, and even military readiness.


Citing national security concerns, Obama issued another order on Friday blocking Chinese firm Fujian Grand Chip from buying Aixtron, a German company operating in California that produces crystalline layers used as semiconductors in U.S. weapons systems.

Executive orders aren’t the only means for Obama to act without Congress before he leaves office on Jan. 20.

A new policy on highly skilled immigrants, restrictions on for-profit colleges, and energy efficiency standards are among the matters that the administration wants that don’t require congressional authorization that the Obama administration is moving aggressively in the post-election to complete before Obama exits on Jan. 20.

Executive actions and administrative regulations were planned and considered before the election and not a result of Republican Donald Trump’s victory, White House press secretary Josh Earnest said at a White House press briefing, noting executive actions and regulations take “a lot of preparation.”

“I’m not going to rule out additional executive actions that the administration may take between now and January 20—after all, the president of the United States is the president of the United States until Jan. 20,” Earnest told The Daily Signal, adding:

But what I can rule out are any sort of hastily added executive actions that weren’t previously considered that would just be tacked on at the end. But are there some actions that have been in the pipeline for quite some time that could be announced between now and Jan. 20? That possibility certainly exists, but I don’t have anything to preview at this point.

Politico reported the list of Obama administration actions before leaving office includes:

A U.S. citizenship and immigration policy to make it easier for employers to sponsor highly skilled immigrants;
An Education Department policy to provide debt relief to students at for-profit colleges;
The Transportation Department is moving to ban cellphone calls on commercial flights;
The Occupational Safety and Health Administration could limit exposure to beryllium, a metal used in electronics and aerospace industries believed to pose lung cancer risks; and
The Department of Health and Human Services is seeking to change how doctors and hospitals get paid for administering drugs under Medicare Part B.

The fact that Trump could overturn much executive or administrative actions doesn’t appear to have caused pause, as the Federal Register has grown by 9,000 pages since Nov. 8, said Ryan Young, a fellow with the Competitive Enterprise Institute.

Gina McCarthy, the Environmental Protection Agency administrator, seemed eager for more action in a memo to staff sent to employees after the Nov. 8 election, which was obtained by the Washington Examiner.

“As I’ve mentioned to you before, we’re running—not walking—through the finish line of President Obama’s presidency,” McCarthy wrote. “Thank you for taking that run with me. I’m looking forward to all the progress that still lies ahead.”

Whether the regulations or executive actions are hasty shouldn’t really be the key question, said James Gattuso, a senior research fellow who studies regulatory issues for The Heritage Foundation.

“As far as I’m concerned, if it takes a long time to adopt rules or actions, or if they fly through the process, it doesn’t matter if it’s a bad rule,” Gattuso told The Daily Signal.

Regulations, he said, can be more tedious to overturn than executive orders or executive actions. However, the 1996 Congressional Review Act could be used to roll back many of those regulations, Gattuso said.

The law allows Congress, with the president’s signature, to scrap regulations it opposes, bypassing previous legal procedures in place, while forbidding bureaucrats from imposing rules that are substantially the same.

“No president is willing to sign a bill overturning their own regulation, but they are willing to overturn their predecessor’s regulations,” Gattuso said. “This is a once in a decade chance, really a once in several decades’’ opportunity, to roll back regulations.”

House Majority Leader Kevin McCarthy, R-Calif., and 21 House committee chairmen warned against a rush for regulations in a letter to agency heads, pledging to used the Congressional Review Act if need be. The Nov. 15 House Republican letter said:

As you are aware, such action often involves the exercise of substantial policymaking discretion and could have far-reaching impacts on the American people and the economy. Considering these potential consequences, we write to caution you against finalizing pending rules or regulations in the administration’s last days.

By refraining from acting with undue haste, you will ensure that agency staff may fully assess the costs and benefits of rules, making it less likely that unintended consequences will harm consumers and businesses.

Moreover, such forbearance is necessary to afford the recently elected administration and Congress the opportunity to review and give direction concerning pending rulemakings.

Should you ignore this counsel, please be aware that we will work with our colleagues to ensure that Congress scrutinizes your actions—and, if appropriate, overturns them—pursuant to the Congressional Review Act.

On Nov. 8, the Federal Register contained 78,300 pages, and as of Dec. 2, it had increased to 87,297 pages, Young said. Further, since Election Day, there were 144 new proposed regulations from federal agencies, and 243 regulations that were finalized.

“We could see a midnight rush the likes of which we haven’t seen before,” Young, of the Competitive Enterprise Institute, told The Daily Signal.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 266

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 208

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 33

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 0

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 164

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 284

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 171

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 208

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover How Indovinya's Innovations Boost Sustainable Agriculture

Updated Category News Views 93

Unlocking the Potential of Biopesticides in Agriculture Indovinya introduces innovative solutions to enhance the use of biologically based products amidst a growing drive for sustainable crop protection. Advancements in Biopesticide Utilization The adoption of biopesticides as an alternative to traditional agrochemicals is gaining traction. However, the integration of...

Continue Reading
SCHMID Group Expands Influence with New Equipment Orders

Updated Category News Views 155

SCHMID Group Strengthens Market Position with New Orders In an exciting development from the SCHMID Group, a key player in the equipment manufacturing sector, the company has recently secured significant orders for Panel Level Packaging (PLP) and modified Semi-Additive (mSAP) production equipment. The orders mark a noteworthy advance as SCHMID continues to bolster its...

Continue Reading
X4 Pharmaceuticals Completes Major Equity Financing and Leadership Shift

Updated Category News Views 178

Major Equity Financing by X4 Pharmaceuticals X4 Pharmaceuticals has made headlines recently with its announcement of a significant private equity financing round totaling $60 million. This funding is primarily geared towards advancing the company’s promising treatment for rare immune system diseases, demonstrating their commitment to improving patient outcomes. Leading...

Continue Reading
IGI Secures Fast Track from FDA for Promising Cancer Treatment

Updated Category News Views 124

IGI Receives Fast Track Designation for ISB 2001 Results from the dose-escalation portion of the Phase 1 clinical study of ISB 2001, an innovative treatment for heavily pretreated multiple myeloma patients, will be showcased at an upcoming major oncology conference. This exciting news highlights IGI's continued progress in developing groundbreaking therapies. About ISB...

Continue Reading
Prospera Energy Reports Strong Financial Performance for 2024

Updated Category News Views 163

Prospera Energy's Transformative Year: A Deep Dive into 2024 Financial Results In the recent strategic realignment, Prospera Energy Inc. (TSX.V: PEI, OTC: GXRFF) has successfully pivoted under new leadership, making significant strides in enhancing its production capabilities and financial outlook. This transformation was marked by key appointments, including Shubham Garg...

Continue Reading